Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONNASDAQ:BRTXNASDAQ:MGRXNASDAQ:OTRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$6.88+2.7%$9.16$6.20▼$3,499.51$4.00M1.1356,749 shs26,620 shsBRTXBioRestorative Therapies$1.79+7.8%$1.75$1.03▼$2.55$13.43M77.73540,188 shs36,494 shsMGRXMangoceuticals$1.89+11.8%$1.98$1.32▼$7.66$9.77M2.45207,936 shs536,774 shsOTRKOntrak$1.59+1.3%$1.53$1.27▼$5.53$6.71M2.3450,709 shs33,535 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+2.69%-1.01%-8.39%-92.28%-99.76%BRTXBioRestorative Therapies+7.83%+14.38%+4.68%-6.28%+38.76%MGRXMangoceuticals+11.83%+19.62%+4.42%-57.34%-97.96%OTRKOntrak+1.27%+1.27%+7.43%+6.71%-60.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion1.0224 of 5 stars3.32.00.00.00.00.00.6BRTXBioRestorative Therapies3.3183 of 5 stars3.55.00.00.00.73.31.3MGRXMangoceuticals0.3629 of 5 stars0.02.00.00.02.31.70.0OTRKOntrak2.5113 of 5 stars3.55.00.00.01.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.50Moderate Buy$11,758.50170,808.43% UpsideBRTXBioRestorative Therapies 3.00Buy$18.00905.59% UpsideMGRXMangoceuticals 0.00N/AN/AN/AOTRKOntrak 3.00Buy$45.002,730.19% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$54.60K73.33N/AN/A($125.39) per share-0.05BRTXBioRestorative Therapies$391K34.36N/AN/A$2.45 per share0.73MGRXMangoceuticals$511.08K19.12N/AN/A$0.54 per share3.50OTRKOntrak$10.18M0.66N/AN/A$5.56 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$4.91MN/A0.00N/AN/A-12,845.05%-422.87%-201.15%N/ABRTXBioRestorative Therapies-$14.41M-$1.47N/AN/AN/A-2,697.08%-98.49%-75.23%8/12/2025 (Estimated)MGRXMangoceuticals-$9.21M-$4.64N/A∞N/A-1,237.00%-138.00%-118.88%N/AOTRKOntrak-$27.92M-$15.81N/AN/AN/A-237.77%-171.34%-113.42%8/6/2025 (Estimated)Latest ACON, BRTX, MGRX, and OTRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025OTRKOntrak-$1.24-$1.65-$0.41-$1.65N/A$2.02 million5/15/2025Q1 2025ACONAclarion-$1,447.20-$9.32+$1,437.88-$9.32$0.02 million$0.02 million5/15/2025Q1 2025MGRXMangoceuticalsN/A-$1.29N/A-$1.29N/A$0.11 million5/14/2025Q1 2025BRTXBioRestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million4/14/2025Q4 2024OTRKOntrak-$1.35-$9.54-$8.19-$9.54$3.08 million$3.08 million3/27/2025Q4 2024BRTXBioRestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million3/20/2025Q4 2024MGRXMangoceuticalsN/A-$1.01N/A-$1.01N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/ABRTXBioRestorative TherapiesN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/AOTRKOntrakN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A2.802.80BRTXBioRestorative TherapiesN/A2.952.95MGRXMangoceuticalsN/A0.070.07OTRKOntrak0.191.171.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%BRTXBioRestorative Therapies69.38%MGRXMangoceuticals56.72%OTRKOntrak12.95%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%BRTXBioRestorative Therapies25.50%MGRXMangoceuticals16.00%OTRKOntrak1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7582,000505,000Not OptionableBRTXBioRestorative Therapies77.51 million5.16 millionNot OptionableMGRXMangoceuticals35.17 million1.51 millionNot OptionableOTRKOntrak2504.22 million4.14 millionNo DataACON, BRTX, MGRX, and OTRK HeadlinesRecent News About These CompaniesOntrak Inc (OTRK) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...May 21, 2025 | finance.yahoo.comOntrak (NASDAQ:OTRK) Shares Up 1.9% - Here's WhyMay 20, 2025 | americanbankingnews.comOntrak Health to Report 2025 First Quarter Financial Results on May 20, 2025May 19, 2025 | businesswire.comOntrak reports Q4 EPS ($9.29) vs. ($4.02) last yearApril 15, 2025 | markets.businessinsider.comOntrak, Inc. (NASDAQ:OTRK) Q4 2024 Earnings Call TranscriptApril 15, 2025 | msn.comOntrak Health to Report 2024 Fourth Quarter Financial Results on April 14, 2025April 10, 2025 | businesswire.comOntrak Secures Medicaid Provider Designation in Two New States, Enhancing Direct Service Delivery CapabilitiesApril 4, 2025 | finance.yahoo.comOntrak secures Medicaid provider designation in two new statesApril 4, 2025 | markets.businessinsider.comOntrak Health and Sentara Health Plans Execute Three-year Contract Extension Following Several ExpansionsFebruary 19, 2025 | finance.yahoo.comOntrak extends strategic partnership with Sentara Health Plans in VirginiaFebruary 19, 2025 | markets.businessinsider.comOntrak Inc. (OTRK) Partners with Intermountain Health to Deliver AI-Powered Behavioral Health SolutionsJanuary 14, 2025 | msn.comOntrak, Inc. (OTRK) Reports Q3 Loss, Lags Revenue EstimatesNovember 13, 2024 | zacks.comOntrak Health Announces 2024 Third Quarter Financial ResultsNovember 13, 2024 | businesswire.comOntrak, Inc. (OTRK) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseNovember 6, 2024 | zacks.comOntrak Health Expands Behavioral Health Solutions with Sentara Health Plans for Commercial and Marketplace PopulationsNovember 6, 2024 | finance.yahoo.comOntrak Health Collaborates with Major Northeast Regional Plan to Bridge HEDIS Care Gaps Using Ontrak Quality SolutionOctober 9, 2024 | finance.yahoo.comAnalysts Predict a $4 Target for Ontrak Inc (OTRK) Stock—What Could Drive It There?October 9, 2024 | bovnews.comONTRAK INC. DL -,0001 (HY10.DU)September 21, 2024 | au.finance.yahoo.comOntrak Inc (HY10.MU)September 21, 2024 | au.finance.yahoo.comOntrak Inc. (HY10.SG)September 21, 2024 | au.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACON, BRTX, MGRX, and OTRK Company DescriptionsAclarion NASDAQ:ACON$6.88 +0.18 (+2.69%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$6.88 +0.00 (+0.07%) As of 05/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.BioRestorative Therapies NASDAQ:BRTX$1.79 +0.13 (+7.83%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.74 -0.05 (-3.07%) As of 05/27/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Mangoceuticals NASDAQ:MGRX$1.89 +0.20 (+11.83%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.89 0.00 (0.00%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Ontrak NASDAQ:OTRK$1.59 +0.02 (+1.27%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.31%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. Ontrak, Inc. was incorporated in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
